Inovio up 1% on encouraging INO-3106 results

Apr. 03, 2019 9:46 AM ETInovio Pharmaceuticals, Inc. (INO)By: Douglas W. House, SA News Editor7 Comments
  • Inovio Pharmaceuticals (NASDAQ:INO +1.4%) is up on light volume in early trade on the heels of results from a pilot study of INO-3106 in two patients with recurrent respiratory papillomatosis, a rare HPV-associated disease characterized by persistent noncancerous tumor growths in the airways. The data were presented at AACR in Atlanta.
  • Surgery to remove the growths, usually multiple times each year, is the only current treatment.
  • Following their last dose of INO-3106, a non-invasive immunotherapy, both patients have been surgery-free, one for two years and the other for one year.
  • Development is ongoing.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.